It's really about establishing the CPACS targets and pure FTO inhibiton synergy targets with approved medicines.
Why try to take patients away from approved medicine when you can harmonize with the currently approved therapies making them work better and in some cases be safer for the heart.
Attempting to put a value on that is difficult, but I would say it's conservatively worth multiples of the current market cap. Bisantrene has shown excellent efficacy in combination with antimetabolites with no clinical signs of cardiotoxicity. Both mechanisms appear universal, so it's unknow how big that market could be.
AML Valuation, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.045(2.86%) |
Mkt cap ! $260.8M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.59 | $1.51 | $157.3K | 101.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3901 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.54 | 1000 | 1 |
View Market Depth
| Last trade - 13.53pm 11/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |